Combined therapy in diabetic macular edema

Stanga, 1999, Ocular manifestations of diabetes mellitus, Curr Opin Ophthalmol, 10, 483, 10.1097/00055735-199912000-00018 Romero-Aroca, 2011, Managing diabetic macular edema: the leading cause of diabetes blindness, World J Diabetes, 2, 98, 10.4239/wjd.v2.i6.98 Klein, 1984, The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years, Arch Ophthalmol, 102, 520, 10.1001/archopht.1984.01040030398010 Rodriguez-Villalobos, 2005, Diabetic retinopathy: twelve-year incidence and progression, Cir Cir, 73, 79 Klein, 1994, The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy, Arch Ophthalmol, 112, 1217, 10.1001/archopht.1994.01090210105023 Gardner, 2002, Diabetic retinopathy: more than meets the eye, Surv Ophthalmol, 47, S253, 10.1016/S0039-6257(02)00387-9 Bhagat, 2009, Diabetic macular edema: pathogenesis and treatment, Surv Ophthalmol, 54, 1, 10.1016/j.survophthal.2008.10.001 Ehrlich, 2010, Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process, Acta Ophthalmol, 88, 279, 10.1111/j.1755-3768.2008.01501.x Aiello, 1994, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, N Engl J Med, 331, 1480, 10.1056/NEJM199412013312203 Bresnick, 1983, Diabetic maculopathy. A critical review highlighting diffuse macular edema, Ophthalmology, 90, 1301, 10.1016/S0161-6420(83)34388-8 Ogata, 2001, Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury, Curr Eye Res, 22, 245, 10.1076/ceyr.22.4.245.5506 Mori, 2002, Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor, Invest Ophthalmol Vis Sci, 43, 2428 Desmettre, 2003, Transpupillary thermotherapy (TTT) with short duration laser exposures induce heat shock protein (HSP) hyperexpression on choroidoretinal layers, Lasers Surg Med, 33, 102, 10.1002/lsm.10193 Peyman, 1971, Chorioretinal diffusion of peroxidase before and after photocoagulation, Invest Ophthalmol, 10, 489 Peyman, 1972, Peroxidase diffusion in the normal and laser-coagulated primate retina, Invest Ophthalmol, 11, 35 Antonetti, 1999, Molecular mechanisms of vascular permeability in diabetic retinopathy, Semin Ophthalmol, 14, 240, 10.3109/08820539909069543 Wilson, 2003, Argon laser photocoagulation-induced modification of gene expression in the retina, Invest Ophthalmol Vis Sci, 44, 1426, 10.1167/iovs.02-0622 1985, Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol, 103, 1796, 10.1001/archopht.1985.01050120030015 Blankenship, 1991, Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications, Graefes Arch Clin Exp Ophthalmol, 229, 62, 10.1007/BF00172263 Pacella, 2013, Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema, Clin Ophthalmol, 7, 1423, 10.2147/OPTH.S48364 Ciulla, 2014, Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant, Expert Opin Pharmacother, 15, 953, 10.1517/14656566.2014.896899 Tasman, 2012, 358 Goyal, 2011, Meta-analysis and review on the effect of bevacizumab in diabetic macular edema, Graefe's Aarch Clin Exp Ophthalmol, 249, 15, 10.1007/s00417-010-1452-4 van der Reis, 2011, A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections, Retina, 31, 1449, 10.1097/IAE.0b013e3182278ab4 Lee, 2011, Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema, Korean J Ophthalmol, 25, 299, 10.3341/kjo.2011.25.5.299 Wang, 2011, Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema, Chin Med J, 124, 352 Grisanti, 2007, Bevacizumab: off-label use in ophthalmology, Indian J Ophthalmol, 55, 417, 10.4103/0301-4738.36474 Ozkiris, 2009, Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema, Eye, 23, 616, 10.1038/eye.2008.40 Arevalo, 2009, Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up, Graefe's Arch Clin Exp Ophthalmol, 247, 735, 10.1007/s00417-008-1034-x 1991, Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group, Ophthalmology, 98, 766 Lee, 1991, Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results, Ophthalmology, 98, 1594, 10.1016/S0161-6420(91)32082-7 Bandello, 2011, Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema, Clin Ophthalmol, 5, 1303, 10.2147/OPTH.S17423 Chen, 2014, Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials, PLOS ONE, 9, e115797, 10.1371/journal.pone.0115797 Martin, 2012, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology, 119, 1388, 10.1016/j.ophtha.2012.03.053 Elman, 2012, Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results, Ophthalmology, 119, 2312, 10.1016/j.ophtha.2012.08.022 Faghihi, 2008, Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema, Eur J Ophthalmol, 18, 941, 10.1177/112067210801800614 Group, 2011, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 364, 1897, 10.1056/NEJMoa1102673 Nguyen, 2010, Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study, Ophthalmology, 117, 2146, 10.1016/j.ophtha.2010.08.016 Massin, 2010, Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study, Diabetes Care, 33, 2399, 10.2337/dc10-0493 Mitchell, 2011, The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema, Ophthalmology, 118, 615, 10.1016/j.ophtha.2011.01.031 Schmidt-Erfurth, 2014, Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study, Ophthalmology, 12, 1045, 10.1016/j.ophtha.2013.11.041 Treatment for CI-DME in eyes with very good VA study (Protocol V). ClinicalTrials.gov. clinicaltrials.gov/ct2/show/NCT01909791. Updated November 20, 2013 [accessed 15.01.14]. Beck, 2009, Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema, Arch Ophthalmol, 127, 245, 10.1001/archophthalmol.2008.610 Bandello, 2012, New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel, Eye, 26, 485, 10.1038/eye.2011.337 Kreutzer, 2010, Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema, Ophthalmologica, 224, 258, 10.1159/000284466 Marey, 2011, Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema, Clin Ophthalmol, 5, 1011, 10.2147/OPTH.S22103 Forte, 2010, Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema, Eye, 24, 1325, 10.1038/eye.2010.23 Solaiman, 2010, Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema, Retina, 30, 1638, 10.1097/IAE.0b013e3181e1ed07 Arevalo, 2013, Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months, Retina, 33, 403, 10.1097/IAE.0b013e3182695b83 González, 2008, Tratamiento del edema macular diabético clínicamente significativo con láser Nd:Yag subumbral de doble frecuencia, Medicina Universitaria, 10, 190 Googe, 2011, Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation, Retina, 31, 1009, 10.1097/IAE.0b013e318217d739 Soheilian, 2012, Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema, Retina, 32, 314, 10.1097/IAE.0b013e31822f55de Chan, 2012, Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab, and laser photocoagulation for refractory diabetic macular edema: a pilot study, Retina, 32, 672, 10.1097/IAE.0b013e31823043c6